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Abstract
16p13.11 genomic copy number variants are implicated in several neuropsychiatric disorders, such as schizophrenia, autism,
mental retardation, ADHD and epilepsy. The mechanisms leading to the diverse clinical manifestations of deletions and
duplications at this locus are unknown. Most studies favour NDE1 as the leading disease-causing candidate gene at
16p13.11. In epilepsy at least, the deletion does not appear to unmask recessive-acting mutations in NDE1, with
haploinsufficiency and genetic modifiers being prime candidate disease mechanisms. NDE1 encodes a protein critical to cell
positioning during cortical development. As a first step, it is important to determine whether 16p13.11 copy number
change translates to detectable brain structural alteration. We undertook detailed neuropathology on surgically resected
brain tissue of two patients with intractable mesial temporal lobe epilepsy (MTLE), who had the same heterozygous NDE1-
containing 800 kb 16p13.11 deletion, using routine histological stains and immunohistochemical markers against a range of
layer-specific, white matter, neural precursor and migratory cell proteins, and NDE1 itself. Surgical temporal lobectomy
samples from a MTLE case known not to have a deletion in NDE1 and three non-epilepsy cases were included as disease
controls. We found that apart from a 3 mm hamartia in the temporal cortex of one MTLE case with NDE1 deletion and
known hippocampal sclerosis in the other case, cortical lamination and cytoarchitecture were normal, with no differences
between cases with deletion and disease controls. How 16p13.11 copy changes lead to a variety of brain diseases remains
unclear, but at least in epilepsy, it would not seem to be through structural abnormality or dyslamination as judged by
microscopy or immunohistochemistry. The need to integrate additional data with genetic findings to determine their
significance will become more pressing as genetic technologies generate increasingly rich datasets. Detailed examination of
brain tissue, where available, will be an important part of this process in neurogenetic disease specifically.
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Introduction
Copy number variants are insertions, deletions or duplications
of segments of DNA. They can be found in healthy individuals, or
be associated with disease. They have been the focus of
considerable recent interest in neurological disorders [1,2]. In
particular, 16p13.11 copy number changes are associated with
schizophrenia [3], mental retardation [4,5], attention-deficit
hyperactivity disorder [6] and both idiopathic generalised [7–9]
and focal epilepsies [10]. In our previous study, we found 23/3812
patients had .100 kb deletions at 16p13.11, with Nuclear
Distribution gene E homolog 1 (NDE1) involved in 22/23 [10].
NDE1 encodes a protein that belongs to the highly-conserved
nuclear distribution protein family. The Nde1 protein predomi-
nantly interacts both with Lissencephaly-1 (Lis-1), a protein
essential for lamination of the cerebral cortex [11–13], and with
dynein, a cytoplasmic motor protein that directs cellular cargos
towards the ‘minus end’ of microtubules [11,14–16]. Together, the
Nde1-Lis-1-dynein complex mediates a range of intracellular
motility activities, including the transport of organelles to the
centrosomes, the orientation of mitotic spindles, the separation of
chromosomes during mitosis and the assembly of centrosomes and
spindles [13,16–22], all of which are important for cortical
development.
NDE1 loss has been suggested a prime candidate for disease
mechanisms associated with 16p13.11 deletion [4,23]. Deficiency
of Lis-1 and Nde1 expression in Lis-1 and Nde1 mutant mice and
Nde1 knockout mice results in a marked loss of cortical lamination,
reduced brain size and a reduction in precursor cell division and
segregation [11–13,22]. In humans, LIS1 haploinsufficiency (from
a deletion at 17p13.3) results in Type 1 Lissencephaly or Miller
Dieker syndrome, where patients have gross cortical dyslamina-
tion, a resulting smooth or under-folded cortex, and may
experience epileptic seizures [24,25]. Similarly, patients with
homozygous frameshift mutation in NDE1 show microlissence-
phaly (reduced brain size and simplified cortex) and experience
seizures starting early in life [26,27]. Heterozygous deletion of
NDE1 specifically may be a prime cause of epilepsy, both focal and
idiopathic generalised, associated with 16p13.11 deletion
[7,10,28]. Testing of this hypothesis directly in humans is difficult
as the deletion is rare, and brain tissue is almost never available
from patients with idiopathic generalised epilepsies. In our cohort
of patients with focal epilepsy however, there were two patients
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16p13.11 deletion, who had previously undergone temporal
lobectomy as treatment for their drug-resistant seizures. This
surgically-resected material allows direct examination in the target
tissue of the consequences of heterozygous NDE1 deletion. We
tested the hypothesis that NDE1 loss would cause cortical
dyslamination, using immunohistochemistry for a range of layer-
specific, neural precursor and migratory cell markers.
Results
The disease cases 1 and 2 both had the same 800 kb 16p13.11
deletion including NDE1.
Histological staining
The temporal cortex of Case 1, Case 2 and disease controls
appeared normal with no cell loss or dyslamination evident in
H+E, LFB or anti- Neuronal Nuclei (NeuN) labelled sections
(Figure 1). LFB and Alcian Blue stains revealed a well-defined
nodule of 3 mm in diameter, with an accumulation of
metachromatic material, in the subcortical white matter of the
middle temporal gyrus of Case 1 (Figure 2A–B). This nodule was
composed of small, round cells that were immunopositive for
microtubule-associated protein 2 (MAP2; Figure 2C–D) but not
immunopositive for glial fibrillary acidic protein (GFAP), NeuN,
synaptophysin or neurofilaments. These MAP2-immunopositive
cells intermingled with larger, NeuN-immunopositive neurons
and GFAP-immunopositive reactive astrocytes inside the nodule.
Together, these neuropathological findings define the nodule as a
hamartia (a small hamartoma [29,30]). The overlying cortex
appeared normal and serial sections taken from either side
showed that the hamartia was neither part of a glio-neuronal
tumour nor part of a larger malformation. Case 2 and other
disease controls did not show pathological features indicative of a
hamartia.
The hippocampus of Case 1 was normal, with no loss of cells in
H+E, LFB and anti-NeuN labelled sections. Pre-operative
magnetic resonance imaging (MRI) showed that Case 2 had a
smaller left hippocampus compared to the right (Figure 3A).
Microscopic examination of Case 2’s surgically-resected left
hippocampus revealed a marked loss of NeuN-immunopositive
neurons in the cornu Ammonis (CA) 4, 3 and 1 (Figure 3B). The
loss of NeuN-immunopositive cells in CA regions was also noted
in the MTLE control without NDE1 deletion (Figure 3C).
Granule cell dispersion was present in Case 2. A dense matrix of
GFAP-immunopositive cells and processes was observed through-
out the hippocampus of Case 2, particularly in CA regions
(Figure 3D). Dynorphin (Figure 3E) and neuropeptide Y
immunoreactivities were evident in the inner, middle and outer
molecular layers of the dentate gyrus of Case 2, confirming mossy
fibre spouting. Together, these features were consistent with
hippocampal sclerosis, a common pathology observed in MTLE
[31].
Figure 1. The temporal cortex of Case 2. The cortical lamination of
the temporal cortex of Case 2 was normal, as compared to the MTLE
case without NDE1 deletion and non-epilepsy surgical controls.
Scale=200 mm.
doi:10.1371/journal.pone.0034813.g001
Figure 2. Hamartia in the temporal cortex of Case 1. LFB (A) and
Alcian Blue (B) stains showed the location of the hamartia within the
middle temporal gyrus (*). Small, round cells inside the hamartia were
immunopositive for MAP2 as viewed at a low (C) and high (D)
magnification. Scale=100 mm (A–C), 20 mm (D).
doi:10.1371/journal.pone.0034813.g002
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We examined the lamination of the temporal cortex and
anatomy of the hippocampus of Case 1, Case 2 (Figure 4A, Figure
S1A) and disease controls (Figure 4B, Figure S1B) using layer-
specific immunohistochemical markers: anti-microtubule-associat-
ed protein 1B (MAP1B), N200, SMI32, anti-calretinin, anti-
calbindin and anti-parvalbumin. These layer-specific markers
label cell types specifically distributed within certain human
cortical layers [32–35]. The white matter of Case 1, Case 2 and
disease controls was investigated using SMI94 and anti-nogo-A
antibodies. Nogo-A is a reticulin family protein expressed mostly
by oligodendrocytes in the brain [36].
The pattern of immunolabelling with layer-specific and white
matter markers was similar for Case 1, Case 2 and disease
controls. In the temporal cortex, many MAP1B-, N200-, SMI32-,
calretinin-, calbindin-, parvalbumin-immunopositive cells were
observed in the upper cortical layers (II and III) of Case 1, Case 2
(Figure 4A, Figure S1A) and disease controls (Figure 4B, Figure
S1B). A few MAP1B-, N200-, SMI32-, calbindin- and parvalbu-
min- immunopositive cells were also observed in the lower cortical
layers (IV, V and/or VI) of all cases. All immunopositive cells in
Case 1 and 2 appeared normal with no atypical or dysplastic
features. Thick, SMI94-immunopositive radial fibres were pre-
dominantly observed from cortical layer IV to the white matter of
all cases, with fewer horizontal fibres highlighted in layer I of Case
1, Case 2 (Figure 4A) and disease controls (Figure 4B). In the white
matter of all cases, nogo-A-immunopositive cells were small and
round, with labelling restricted to the scant cell body of
oligodendrocytes. Nogo-A-immunopositive cells were found pre-
dominantly in the white matter rather than the gray matter.
In the hippocampus of all cases, MAP1B-, N200-, SMI32-
calretinin-, calbindin- and parvalbumin-immunopositive cells were
observed in the CA regions and subiculum. There were visibly
fewer N200-, SMI32-, calretinin-, calbindin- and parvalbumin-
immunopositive cells in the CA regions of Case 2 and the MTLE
control without NDE1 deletion, than in Case 1 and non-epilepsy
controls, in keeping with the presence of hippocampal sclerosis in
the MTLE disease control and Case 2. MAP1B- and calbindin-
immunopositive granule cells were evident in the granule cell layer
of all cases. Parvalbumin-immunopositive processes or synapses
were often observed between granule cells in the GCL and the
Figure 3. Hippocampal sclerosis in Case 2. (A) A coronal MRI image of Case 2 showing left hippocampal atrophy (*; inset). No cerebral
malformations were evident. The histology showed hippocampal sclerosis: (B) NeuN-immunopositive cells were lost in the cornu Ammonis (CA)
regions of the left hippocampus of Case 2, as seen in the MTLE control case without NDE1 deletion (C). (D) Strong GFAP-immunoreactivity was
observed in all regions of the hippocampus of Case 2. (E) Dynorphin-immunoreactivity was observed throughout the molecular layer of Case 2,
demonstrating the presence of mossy fibre spouting. GCL=granule cell layer, MOL=molecular cell layer. Scale=100 mm (B–E).
doi:10.1371/journal.pone.0034813.g003
Figure 4. MAP1B, SMI32, Calbindin and SMI94-immunopositive
labelling in the temporal cortex of Case 2 and the MTLE
control. MAP1B and calbindin-immunopositive cells were predomi-
nantly observed in the upper cortical layers, while SMI32-immunopo-
sitive cells and processes were mainly found in the lower cortical layers
of MTLE cases with (A) or without NDE1 deletion (B). Immunoreactivity
of SMI94 was observed in the lower cortical layers and white matter of
both cases. Scale=200 mm (A, B).
doi:10.1371/journal.pone.0034813.g004
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oligodendrocytes were evident in the white matter of all cases.
Precursor and migratory cell markers
Antibodies against nestin, GFAPdand PAX6 label neural
precursor cells [37–40], while antibodies against DCX and reelin
label migratory cells in the developing and adult mammalian brain
[41–43]. The immunolabelling of these markers was not markedly
different between Case 1, Case 2 and disease controls.
Nestin-, GFAPd-, PAX6-, DCX- and reelin-immunopositive
cells were predominantly observed in cortical layer I and white
matter of Case 1, Case 2 (Figure 6A–C, 7A–B) and disease
controls. GFAPd- and DCX-immunopositive cells were binucle-
ated or multinucleated with glial-like processes. Nestin-immuno-
positive blood vessels were observed throughout the cortex. A few
GFAPd-immunopositive cells were observed in the deeper cortex
and in the white matter of all cases; they were often situated
around blood vessels. PAX6- and small, reelin-immunopositive
cells could also be seen in the other cortical layers of all cases.
In the hippocampus, GFAPd-immunopositive cells were
observed in all CA regions, particularly in the sclerotic
hippocampus of Case 2 and the MTLE control case without
NDE1 deletion. PAX6- and DCX-immunopositive cells were
observed throughout the hippocampus, particularly in the CA4
and granule cell layer of all cases. Large, reelin-immunopositive
cells were observed in the CA4 region and in the molecular layer
of the dentate gyrus, while small reelin-immunopositive cells were
observed throughout the hippocampus.
NDE1
The immunoreactivity of NDE1 was observed in the cytoplasm
of neurons throughout the temporal cortex and hippocampus of
Case1 and 2 and disease controls (Figure 8). No marked difference
in immunolabelling was observed between Case 1, Case 2 and
disease controls.
Multidrug resistance-related protein 1
The chromosomal region 16p13.11 also contains ABCC1, which
encodes the multidrug resistance-related protein 1 (MRP1). We
investigated MRP1 expression using MRPr1, an antibody which
has been used in previous human studies [44,45]. MRPr1-
immunopositive blood vessels were observed throughout temporal
cortex and hippocampus of Case 1, Case 2 (Figure 9A–B) and
disease controls. Many MRPr1- immunopositive glial cells and
fibres were also observed in the cortical layer I and white matter of
the temporal cortex and the hippocampal CA regions. Most
MRPr1-immunopositive glial cells were found around blood
vessels (Figure 9B). The glial expression of anti-MRP1 has been
previously described in studies using surgical MTLE tissue without
Figure 5. Parvalbumin-immunopositive labelling in the hippo-
campus of Case 2. A few numbers of parvalbumin-immunopositive
cells were still observed in CA4 (A) and CA2 (B) of the sclerotic
hippocampus of Case 2. Some parvalbumin-immunopositive processes
and plexuses were observed around granule cells (A) and surviving
pyramidal neurons in CA2 (B). CA=cornu Ammonis, GCL=granule cell
layer. Scale=20 mm (A, B).
doi:10.1371/journal.pone.0034813.g005
Figure 6. Nestin, GFAPd and PAX6 immunopositive labelling in
the temporal cortex and hippocampus of Case 2. Nestin- (A) and
GFAPd (B) strongly immunopositive glial-like cells were observed in
cortical layer I and white matter of the temporal cortex and the
hippocampus of Case 2. Nestin-immunopositive cells with short,
unipolar processes were occasionally found in the white matter of
Case 2 (A, middle inset). Small, round PAX6-immunopositive cells were
found throughout the temporal cortex and hippocampus. BV=blood
vessels, CA=cornu Ammonis, GCL=granule cell layer. Scale=20 mm
(A–C), 10 mm (A, middle inset).
doi:10.1371/journal.pone.0034813.g006
Figure 7. DCX and reelin-immunopositive labelling in the
temporal cortex of Case 2. In cortical layer I, DCX-immunopositive
cells with a glial-like morphology clustered in groups of two or three
(arrows, A). DCX-immunopositive cells with short, bipolar processes
were occasionally observed in the upper cortical layers (A inset). Reelin-
immunopositive cells were also observed in cortical layer I (B) and in
deeper cortical layers of Case 2 (B, inset). Scale=10 mm (A, B, insets).
doi:10.1371/journal.pone.0034813.g007
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pattern of MRP1 immunoreactivity to that seen in Case 1 and
Case 2.
Discussion
Two key challenges in disease genetics are to identify
pathogenic genetic changes and to understand how these changes
lead to disease phenotypes. For neuropsychiatric diseases, the
latter challenge is often especially daunting, as direct study of the
organ involved, the brain, is usually impossible. But such studies,
using brain material from patients with the neurological disease in
question, especially those with known genetic abnormalities, are
important as they may provide valuable insights and bounds about
the effects of genetic variants on brain structure and disease
mechanisms. We examined the surgically-resected temporal cortex
and hippocampus of two people with MTLE with identical 800 kb
deletion at 16p13.11, encompassing seven genes, including NDE1
and ABCC1. In Case 1, the white matter of the temporal cortex
contained a hamartia, which was not associated with any overlying
cortical dyslamination or any dysmorphic neurons, balloon cells or
more extensive changes seen in glio-neuronal tumours. In Case 2,
we found neuronal cell loss, gliosis and re-organisation, changes
typical of hippocampal sclerosis. The genetic basis, if any, of
hippocampal sclerosis is unknown: in our previous study [10], only
2/23 patients with 16p13.11 deletions had hippocampal sclerosis,
whilst other microdeletions are also associated with hippocampal
sclerosis [46]. Both hamartia and hippocampal sclerosis occur in
patients with drug-resistant epilepsy [30,47], and are unlikely to be
due to the 16p13.11 deletion.
Case 1 and Case 2 both had a normal, hexalaminar temporal
cortex, housing appropriate layer-specific cell types. No marked
difference was observed for NDE1 immunoreactivity or expression
of proteins associated with cell division and migration in the
temporal cortex or hippocampus of either case in comparison to
disease controls. NDE1 immunoreactivity in both Case 1 and 2
and disease controls was localised to the cytoplasm of neurons,
which is consistent with its role in intracellular transport [22,48].
In animal studies, Nde2/2 mutants have no Nde1 expression
and possess a brain that is a third smaller than controls, while
heterozygous Nde1+/2 mutant mice express a considerable
amount of NDE1 protein, that is only slightly lower than controls
in immunoblotting experiments, and these heterozygous Nde1 +/2
mutant mice have brain size and weight comparable to controls
[12]. Humans with 1 to 3.4 Mb homozygous deletions at
16p13.11 have small stature, dysmorphic features, seizures,
microcephaly or microlissencephaly [4,26]. In humans, the
contrasting phenotypes of duplication and deletion suggest
16p13.11 is a dosage-sensitive region [28]. However, the resected
brain tissue of our two patients with heterozygous 16p13.11
deletion was normal for the parameters we examined. Moreover,
these patients did not have intellectual disability, or any
remarkable abnormalities of appearance or stature. Therefore,
no clear dose-dependency phenomenon is apparent in our two
patients with, at least, loss of one copy of the whole NDE1 gene. If
16p13.11 deletion contributes to brain disease in our two patients
through loss of at least one copy of NDE1, as is the current
favoured hypothesis, then this contribution to disease would not
seem to be through pathology obvious at the light microscopic
level or immunophenotypically-determined dyslamination. The
deletion of NDE1 could act at another, for example submicro-
scopic, level; it is also possible that the deletion unmasks a recessive
mutation on the remaining allele, but this is unlikely given the
normal appearance and cognitive abilities of our two patients and
previous examination of this possibility [10]. Alternatively, loss of
NDE1 in patients with heterozygous NDE1 deletion may possibly
be compensated by other proteins with similar functions such as
LIS1 or NDE1-related protein 1 (NDEL1), a homolog of NDE1
[14,15,49].
Finally, it is possible that at least in our two patients, loss of
NDE1 is not the key contributor to disease (here, epilepsy)
associated with 16p13.11 deletion, suggesting that other candi-
dates and mechanisms need to be sought. Overall, however, the
link between heterozygous deletion of 16p13.11 and epilepsy, and
other neuropsychiatric diseases, is clear [9,10]: this deletion is not
a polymorphism, and is at the very least a disease risk factor. In
Case 1, seizures continued despite surgery, implying that
epileptogenic tissue remained unresected. The 16p13.11 deletion
in this case may therefore have conceivably acted as a risk factor
for epilepsy by subtly altering brain structure beyond the resected
tissue, a possibility we could not test as only resected tissue was
available for analysis. We note, however, that NDE1 is expressed in
the human temporal lobe (e.g. [27], such that if NDE1 deletion
were acting by altering microscopic brain structure, examination
for such changes in the temporal lobe would be a reasonable
strategy: we did not find any alteration with the methods
employed.
Our study illustrates the central role for detailed phenotyping in
interpretation of genetic findings: for neurogenetics, human
neuropathological studies are key, setting boundaries for putative
Figure 9. MRP1-immunopositive labelling in the temporal
cortex and hippocampus of Case 2. (A) Many MRP1-immunopo-
sitive cells and processes were observed in the hippocampus. (B) MRP1-
immunopositive cells were also evident in the temporal cortex (usually
around blood vessels). CA=cornu Ammonis, GCL=granule cell layer,
BV=blood vessel. Scale=50 mm (A), 20 mm (B).
doi:10.1371/journal.pone.0034813.g009
Figure 8. NDE1-immunopositive labelling in the temporal
cortex of Case 2 and MTLE case without NDE1 deletion. The
immunoreactivity of NDE1 (arrows) was predominantly observed in the
cytoplasm of neurons in Case 2 and the epilepsy control.
doi:10.1371/journal.pone.0034813.g008
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anticipate an increasing role for such studies in human genetic
diseases in general.
Materials and Methods
The study was approved by the Joint Research Ethics
Committee of the Institute of Neurology and the National
Hospital for Neurology and Neurosurgery. The work described
has been carried out in accordance with The Code of Ethics of the
World Medical Association (Declaration of Helsinki). Written
informed consent was obtained for research. We examined
surgically-resected temporal cortical and hippocampal tissue from
two MTLE patients with confirmed 16p13.11 deletion. Their
clinical details and results from genetic analysis are described in
Table 1 and Figure 10. Neither of the patients has learning
disability. No structural abnormalities were observed in MRI,
apart from Case 2 who had a smaller left hippocampus compared
to the right. Surgically-resected temporal cortex and hippocampus
of a patient with MTLE known not to have the deletion of the
entire NDE1 gene, and resected neocortical tissue from three
trauma patients were used as disease controls in immunohisto-
chemical studies (Table 1). The three trauma patients were not
tested for the 16p13.11 deletion, but the frequency of this deletion
in patients with focal epilepsy was 0.6%, and the deletion was not
observed in unselected controls [10], so it is very unlikely that all
these three (or indeed any one) of the disease control patients had
the deletion.
All surgical tissue was fixed, processed and paraffin-embedded
within one week following surgery. Routine histology staining,
including haematoxylin and eosin (H+E) and luxol fast blue (LFB),
was performed. Alcian Blue, an acid-mucosubstance stain, was
used in Case 1 to investigate the observed hamartia. Automated
immunohistochemistry was performed using Bond Max Automat-
ed Immunostainer and reagents (Leica, UK). 5 mm sections on
adhesive microscopic slides (Raymond A Lamb, UK) were first
processed in dewaxing solution and 100% alcohol. Antigen
retrieval protocols were applied as detailed in Table 2 before
sections were immersed in 3% hydrogen peroxide solution for
5 minutes. Sections were incubated with primary antibodies for
Figure 10. An illustration showing deleted genes in 16p13.11 in Case 1 and Case 2.
doi:10.1371/journal.pone.0034813.g010
Table 1. Clinical details of cases.
MTLE cases with 16p13.11 deletion
Identifier
Gender/
Age
Deletion region
(size)
Chromosome
band Genes Surgery Pathology
Surgery
outcome
Case 1 M/36 chr16:15387380-
16225138 (837,758)
16p13.11 MPV17L, C16orf45, NDE1,
MYH11, C16orf63,
KIAA0430,
ABCC1, ABCC6
Hippocampal and
temporal cortical
resection
Hamartia in the subcortical
white matter of the middle
temporal gyrus. Not all
hippocampal subfields
were available for assessment.
Still
experienced
frequent
seizures
Case 2 F/37 chr16:15387380-
16225138 (837,758)
16p13.11 MPV17L, C16orf45, NDE1,
MYH11, C16orf63, KIAA0430,
ABCC1, ABCC6
Hippocampal and
temporal cortical
resection
Hippocampal sclerosis
(cell loss and gliosis
in CA1, 3 and 4)
Seizure free
after surgery
Control cases
MTLE case without 16p13.11 deletion
Identifier Gender Age Reason for surgery
N1 F 45 Epilepsy
Non-epilepsy cases
N2 F 57 Head injury, brain swelling
N3 M 41 Head injury
doi:10.1371/journal.pone.0034813.t001
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8 minutes. Chromogen activation was achieved using diamino-
benzidine. Sections were dewaxed and rehydrated through xylene
and graded alcohols and taken to water. Antigen retrieval
procedures were applied as described in Table 2. All sections
were outlined using a wax pen before placing flat in an
immunohistochemical humidity chamber. Primary antibodies
were diluted with Dako diluent and then incubated on sections
as detailed in Table 2. NDE1 primary antibody was used at 1:500.
The following day, sections were incubated in Dako Envision
horseradish peroxide solution for 30 minutes. Chromogen activa-
tion was performed using Dako Envision diaminobenzidine and
substrate buffer for 5 minutes. Sections were washed in phosphate
buffer solution between each step. Sections with omission of
primary antibodies or their replacement non-specific IgG were
included in experiments as negative control. Sections were then
processed through graded alcohols and xylene and coverslipped
(TissueTek). A light microscope and camera (Nikon Eclipse 80i
and Sight DS Fi1) were used to visualize sections and to capture
images. Montages were acquired using the JVC camera attached
to an ImagePro Plus system (Media Cybernetics, USA). The
specificity of the antibody against NDE1 was tested (see Figure S2).
Supporting Information
Figure S1 Immunoreactivities of layer-specific markers
in the temporal cortex of Case 2 and the MTLE control.
MAP1B, calretinin, calbindin and parvalbumin-immunopositive
cells were predominantly observed in the upper cortical layers,
while N200- and SMI32-immunopositive cells and processes were
mainly found in the lower cortical layers of MTLE cases with (A)
or without NDE1 deletion (B). Immunoreactivity of SMI94 was
observed in the lower cortical layers and white matter of both
cases. Scale=200 mm (A, B).
(PDF)
Figure S2 The specificity of the antibody against NDE1.
Immunoblotting experiment detected NDE1 at ,38 kDa, the
expected molecular weight of the protein, in the lysate from the
resected temporal cortex of patient with mesial temporal lobe
epilepsy.
(TIF)
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